Two Sigma Investments — BBIO Trade History

Quarter-by-quarter changes in the BRIDGEBIO PHARMA INC position · CUSIP 10806X102
Currently held · 6 YearsFirst seen: 2020 Q3
QuarterFiledActivitySharesΔ SharesΔ %Value% Port.
2026 Q22026-08-14Add4,722,1851,601,554+51.3%$351.7M0.26%
2026 Q12026-05-15Add3,120,6311,173,584+60.3%$231.7M0.19%
2025 Q42026-02-17Reduce1,947,047-381,894-16.4%$148.9M0.21%
2025 Q32025-11-14Reduce2,328,941-10,126-0.4%$121.0M0.18%
2025 Q22025-08-14Add2,339,0671,495,746+177.4%$101.0M0.18%
2025 Q12025-05-15Add843,321604,785+253.5%$29.2M0.06%
2024 Q42025-02-14Reduce238,536-142,706-37.4%$6.5M0.01%
2024 Q32024-11-14Reduce381,242-184,210-32.6%$9.7M0.02%
2024 Q22024-08-14Reduce565,452-179,148-24.1%$14.3M0.03%
2024 Q12024-05-15Reduce744,600-222,197-23.0%$23.0M0.05%
2023 Q42024-02-14Reduce966,797-310,287-24.3%$39.0M0.09%
2023 Q32023-11-14Add1,277,084536,693+72.5%$33.7M0.09%
2023 Q22023-08-14Reduce740,391-39,149-5.0%$12.7M0.03%
2023 Q12023-05-15Add779,540128,329+19.7%$12.9M0.04%
2022 Q42023-02-14Reduce651,211-219,996-25.3%$5.0M0.02%
2022 Q32022-11-14Add871,207719,944+476.0%$8.7M0.03%
2022 Q22022-08-15Reduce151,263-358,285-70.3%$1.4M0.01%
2022 Q12022-05-16Reduce509,548-96,641-15.9%$5.2M0.01%
2021 Q42022-02-14Add606,189559,467+1197.4%$10.1M0.02%
2021 Q32021-11-15Add46,72231,043+198.0%$2.2M0.01%
2021 Q22021-08-16Reduce15,679-468,149-96.8%$956.0K0.00%
2021 Q12021-05-17Add483,828319,239+194.0%$29.8M0.08%
2020 Q42021-02-16Add164,58932,414+24.5%$11.7M0.03%
2020 Q32020-11-16New132,175132,175$5.0M0.02%
2020 Q22020-08-14
2020 Q12020-05-15
2019 Q42020-02-14
2019 Q32019-11-14
2019 Q22019-08-14
2019 Q12019-05-15
2018 Q42019-02-14
2018 Q32018-11-14
2018 Q22018-08-14
2018 Q12018-05-15
2017 Q42018-02-14
2017 Q32017-11-14
2017 Q22017-08-14
2017 Q12017-05-15
2016 Q42017-02-14
2016 Q32016-11-14

Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.